149. The Evolution Of The Neurohormonal Hypothesis With Dr. Milton Packer: Part 4 – SGLT2 Inhibitors – Under-Promised & Over-Delivered

CardioNerds(Amit Goyal,Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series.

In part 4, Dr. Packer shares his perspective on the revolutionary SGLT2 inhibors. We discuss the mechanisms of action and the data regarding their role in the care of heart failure patients. This episode is particularly historic in that Dr. Packer shares his thoughts about the EMPEROR-PRESERVED trial well before the data was available. Also see Dr. Mark Belkin’s DocWire News article EMPEROR’s New Groove? Empagliflozin Provides Long-Awaited Treatment for HFpEF where Dr. Packer is quoted as saying “we are pleased to have the first trial in patients with HFpEF that shows an unequivocally positive and clinically important result. We are looking forward to many secondary papers that will provide detailed information about what we have found, and what it means for patients.”

Check out theCardioNerdsHeart Failure Success Series Pagefor more heart success episodes and content!

This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees fromAbbvie, Actavis,Amgen, Amarin,AstraZeneca,Boehringer Ingelheim,Bristol Myers Squibb, Casana, CSL Behring,Cytokinetics,Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company,Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics,Teva Pharmaceuticals USA Inc.and Theravance Biopharma Inc.

CardioNerdsHeart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll

CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!